Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Healthcare Realty Trust (HR) Delivers Q3 Beat and Raises Full-Year Guidance

Healthcare Realty Trust (HR) Delivers Q3 Beat and Raises Full-Year Guidance

Key Takeaways

  • Healthcare Realty Trust (NYSE: HR) reported normalized funds from operations (FFO, a key earnings measure for real estate investment trusts) of $0.42 per share, topping the consensus estimate of $0.41.
  • Total revenue came in at $286.64 million, beating analyst expectations by roughly $3.19 million.
  • Management raised its full-year 2026 normalized FFO guidance to a range of $1.65 to $1.67 per share.
  • Same-store cash net operating income (NOI, income generated from property operations) grew 5.1%, supported by cash leasing spreads of 8.6%.
  • GAAP (generally accepted accounting principles) net loss narrowed to $0.05 per share, down from $0.17 per share a year earlier.
  • The board maintained its quarterly dividend of $0.24 per share.
  • For more details on HR's major news, today's price move, price targets, and forecasts, explore the dedicated pages on Tickeron.

Why These Results Matter

Healthcare Realty Trust is the largest publicly traded, pure-play owner and operator of medical outpatient buildings in the United States, a segment that benefits as healthcare delivery shifts away from hospitals toward lower-cost outpatient settings. This quarterly report serves as an important checkpoint on the company's "Healthcare Realty 2.0" strategic plan, which focuses on portfolio optimization, stronger lease economics, and disciplined capital allocation. The third quarter of 2026 indicates whether the turnaround's operating momentum—marked by record leasing, improving occupancy, and rising same-store NOI—can persist, and whether management's guidance increases are translating into durable per-share earnings growth.

Breaking Down the Reported Figures

For the third quarter ended September 30, 2026, Healthcare Realty reported normalized FFO of $0.42 per diluted share, edging past the $0.41 consensus estimate and matching the prior-year figure of $0.41. NAREIT FFO rose to $0.38 per share from $0.34 a year ago. Total revenue of $286.64 million surpassed expectations by about $3.19 million, though it declined from $297.77 million in the prior-year quarter as ongoing property dispositions reduced the top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Operationally, same-store cash NOI increased 5.1%, tenant retention held at 88.0%, and average cash leasing spreads reached 8.6%. The company executed 1.5 million square feet of new and renewal leases. GAAP net loss attributable to common stockholders narrowed to $15.8 million, or $0.05 per share, a meaningful improvement from a loss of $57.7 million, or $0.17 per share, a year earlier.

Management raised 2026 normalized FFO guidance to $1.65–$1.67 per share (from $1.62–$1.66), lifted NAREIT FFO guidance to $1.48–$1.52 per share, and increased same-store cash NOI growth guidance to 5.00%–5.25% (from 4.25%–5.00%).

Market Reaction and Sentiment

Healthcare Realty shares rose more than 3% in the session following the release, reflecting investor approval of the FFO beat and the upwardly revised guidance. Sentiment around the stock has been improving through 2026 as the company's operational turnaround gains traction, with several sell-side analysts raising price targets earlier in the year. The combination of a modest earnings beat, a second consecutive guidance increase, and continued share repurchases reinforces the view that management's strategic plan is producing measurable results.

What to Watch Going Forward

Looking ahead, investors should watch whether the company can sustain its same-store NOI growth near the low-single-digit-to-mid-single-digit range while executing on its portfolio optimization. The raised full-year guidance now implies solid momentum through the fourth quarter, but execution risk remains around signed-but-not-occupied leases converting into rent-paying occupancy. Capital allocation will remain a central theme. Healthcare Realty repurchased 4.2 million shares during the quarter and early October at an average price of $17.74, and it renewed its $500 million buyback authorization. Ongoing dispositions, refinancing activity, and acquisitions within its joint venture with KKR will shape both the balance sheet and per-share earnings. Finally, investors should monitor leverage and interest-rate sensitivity. Net debt to adjusted EBITDA stood at 5.5x, and the company carries substantial near-term liquidity of roughly $1.6 billion. How management balances growth, buybacks, and debt reduction will be an important driver of future results and investor confidence.

Using AI Tools in My Research

In my work tracking healthcare real estate and other sectors, I regularly use Tickeron’s AI Screener as part of the process. It helps filter opportunities based on fundamentals, patterns, and performance metrics more efficiently than manual methods, allowing me to cross-check ideas alongside earnings analysis and identify additional data-driven names quickly.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HR in upward trend: price rose above 50-day moving average on October 30, 2026

HR moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 20 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 51%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on HR as a result. In 46 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.

The 10-day moving average for HR crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +2.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where HR advanced for three days, in 137 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

The Aroon Indicator entered an Uptrend today. In 115 of 226 cases where HR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.

Bearish Trend Analysis

The 10-day RSI Indicator for HR moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 21 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for HR moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

HR broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.560) is normal, around the industry mean (3.134). HR has a moderately low P/E Ratio (-73.846) as compared to the industry average of (30.791). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (1.649). Dividend Yield (0.050) settles around the average of (0.050) among similar stocks. P/S Ratio (5.757) is also within normal values, averaging (6.013).

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. HR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

Industry description

The industry includes companies that publish and market books and magazines/periodicals. John Wiley & Sons, Inc., Meredith Corporation and Scholastic Corporation are some of the biggest companies in this industry. Like many other industries, publishing companies have branched out into online/digital publications (while retaining their original print business), to capture the burgeoning market in electronic media. Business could be cyclical in certain cases, since weak consumer sentiment during an economic downturn might depress sales of some magazines and books.

Market Cap

The average market capitalization across the Publishing: Books/Magazines Industry is 17.39B. The market cap for tickers in the group ranges from 113.09K to 176.55B. WELL holds the highest valuation in this group at 176.55B. The lowest valued company is DIGI at 113.09K.

High and low price notable news

The average weekly price growth across all stocks in the Publishing: Books/Magazines Industry was -2%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was -6%. MPT experienced the highest price growth at 5%, while XRN experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Publishing: Books/Magazines Industry was 112%. For the same stocks of the Industry, the average monthly volume growth was 100% and the average quarterly volume growth was 205%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 61
Price Growth Rating: 53
SMR Rating: 77
Profit Risk Rating: 58
Seasonality Score: -2 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a real estate investment trust

Industry PublishingBooksMagazines

Industry
Real Estate Investment Trusts
Address
3310 West End Avenue
Phone
+1 615 269-8175
Employees
539
Web
https://www.healthcarerealty.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.